Oncology Company Obtains Dismissal in Shareholder Class Action

We secured a dismissal on behalf of an oncology company in a shareholder class action following a 70 percent drop of our client’s stock. The plaintiffs claimed that our client failed to disclose that a new drug application submitted to the FDA contained immature data sets with a lower than expected number of patients responding to the treatment. This matter involved several lawsuits in state and federal courts in Colorado; Delaware; and California. We initially moved to stay the state cases and consolidated the federal actions in Colorado. We ultimately secured a dismissal of the California cases.